Thymosin Alpha-1 Research for Chronic Hepatitis B

Chronic hepatitis B affects hundreds of millions of people worldwide and remains a leading cause of liver cirrhosis, liver failure, and hepatocellular carcinoma. Despite the availability of antiviral therapies, achieving complete viral suppression and immune control remains a clinical challenge for many patients. A 2026 systematic review published in The Cochrane Database of Systematic Reviews — one of the most rigorous forms of evidence synthesis in medicine — took a comprehensive look at whether thymosin alpha-1 (Tα1), a peptide known for its immunomodulatory and antiviral properties, may offer benefit for people living with chronic hepatitis B virus (HBV) infection (Naing C, Ni H, Aung HH, et al., 2026).

What This Study Found

The Cochrane review analyzed data from 10 randomized controlled trials (RCTs) involving 1,349 participants across six countries — Bangladesh, China, Italy, Korea, Singapore, and Taiwan. Trials were published between 1991 and 2018, and follow-up periods ranged from six months to five years. Participants were adults aged 17 to 75, and the majority (77.5%) were male. The trials compared thymosin alpha-1, either alone or combined with other treatments such as interferon, pegylated interferon, lamivudine, or standard antiviral therapy, against placebo or no additional intervention.

The study's primary findings suggest that thymosin alpha-1, compared with control interventions, may reduce all-cause mortality (Risk Ratio [RR] 0.53, 95% CI 0.29 to 0.96; 3 studies, 907 participants) and HBV-related mortality (RR 0.53, 95% CI 0.29 to 0.96; 3 studies, 907 participants). Researchers also found a possible reduction in serious adverse events (RR 0.72, 95% CI 0.53 to 0.99; 5 studies, 1,056 participants) and non-serious adverse events (RR 0.47, 95% CI 0.27 to 0.83; 5 studies, 300 participants).

However, these findings come with important caveats. The certainty of evidence was rated as very low for most outcomes and only low for serious adverse events — the highest rating achieved in the review. Reasons for downgrading the certainty included high or unclear risk of bias in the included trials, imprecision of pooled effect estimates (often reflected in wide confidence intervals that crossed the line of no effect), and in the case of histological improvement, substantial heterogeneity among studies (I² = 74%). The effect of thymosin alpha-1 on HBV-related morbidity remained very uncertain (RR 0.86, 95% CI 0.54 to 1.40), and the single trial reporting health-related quality of life found little to no effect (Mean Difference 0.70, 95% CI -2.55 to 3.95).

Researchers also noted that no ongoing trials were identified, and 16 studies were awaiting assessment due to incomplete reporting — a limitation that further tempers interpretation of the available data.

Clinical Significance

Thymosin alpha-1 is a naturally occurring peptide derived from thymosin fraction 5, a thymic extract first characterized in the 1970s. It plays a role in T-cell maturation and immune regulation, which is why it has attracted interest as an adjunct therapy in chronic viral infections where immune exhaustion is a known obstacle to viral clearance. Its antiviral properties have been the subject of research across multiple disease contexts, including hepatitis B.

The direction of the findings in this Cochrane review is cautiously encouraging: the pooled data suggest thymosin alpha-1 may reduce mortality and adverse events in patients with chronic HBV. However, given the very low certainty of evidence for most outcomes, the authors appropriately conclude that it remains unclear whether thymosin alpha-1 monotherapy or combination therapy meaningfully reduces mortality, morbidity, or adverse events compared to control conditions. The review does not support definitive clinical conclusions.

What this review does highlight is a gap in the evidence base. The included trials were relatively small, many were conducted decades ago with varying methodological standards, and heterogeneity in trial design, dosing, and co-interventions makes cross-trial comparison difficult. The absence of ongoing RCTs, as noted by the authors, is particularly notable given the continued global burden of chronic HBV infection and the theoretical rationale for immunomodulatory approaches.

Current Access and Compliance Context

Thymosin alpha-1 (marketed under the brand name Zadaxin in some countries) is approved or available in parts of Asia, Eastern Europe, and other regions for use in hepatitis B and C, as well as certain immune-deficiency conditions. In the United States, it is not approved by the FDA for any indication, though it may be accessible through compounding pharmacies under physician supervision.

Patients and clinicians considering thymosin alpha-1 should be aware that regulatory status varies significantly by country, and that access outside approved markets carries inherent quality-control considerations. Any therapeutic use should occur within the context of a formal clinical relationship, with careful attention to sourcing, dosing protocols, and monitoring for both efficacy and safety. The Cochrane review included trials using subcutaneous administration at various doses and schedules, reflecting the diversity of protocols used in practice and research settings.

The four trials in this review funded by industry and five by independent research grants also underscore the importance of understanding potential conflicts of interest when evaluating evidence in this space — a consideration that Cochrane reviews are specifically designed to address through systematic methods and transparent risk-of-bias assessment.

What Patients Should Know

If you or someone you care for is living with chronic hepatitis B, this review offers some preliminary signal — but not confirmation — that thymosin alpha-1 may be associated with reduced mortality and fewer adverse events compared to standard care alone or placebo. The key phrase here is may be. The very low certainty of evidence means that further high-quality research is needed before any firm recommendations can be made.

This review should not be interpreted as a reason to pursue thymosin alpha-1 independently or to replace established antiviral therapies. Current standard-of-care treatments for chronic HBV — including nucleos(t)ide analogues such as entecavir and tenofovir — have a well-established evidence base for viral suppression and are recommended by major hepatology guidelines. Any interest in thymosin alpha-1 as a complementary or adjunct strategy should be discussed openly with a qualified healthcare provider who is familiar with both your individual health profile and the current evidence landscape.

Patients should also be aware that thymosin alpha-1 has been generally well-tolerated in existing research, with the Cochrane review suggesting a possible reduction in both serious and non-serious adverse events — though again, the certainty of this finding is low to very low. Self-directed use without medical supervision is not advisable.

Conclusion

The 2026 Cochrane systematic review by Naing and colleagues represents the most comprehensive synthesis to date of randomized trial evidence on thymosin alpha-1 for chronic hepatitis B. While the pooled data suggest possible benefits in mortality and adverse event reduction, the very low to low certainty of evidence means these findings must be interpreted cautiously. Larger, well-designed, and transparently reported RCTs are needed to clarify the role — if any — of thymosin alpha-1 in modern hepatitis B management.

If you are interested in exploring peptide-based or immunomodulatory therapies with a knowledgeable medical professional, the Peptide Association can help connect you with qualified physicians. Visit peptideassociation.org/find-a-doctor to find a doctor in your area who can provide evidence-informed guidance tailored to your health needs.

---

Medical Disclaimer: This article is intended for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. The findings discussed are based on published research and carry significant uncertainty as noted by the original study authors. Always consult a qualified and licensed healthcare provider before making any decisions about your health or medical treatment. Do not disregard or delay seeking professional medical advice based on information presented here.

---

AMA Citation: Naing C, Ni H, Aung HH, et al. Thymosin-α1 for people with chronic hepatitis B. Cochrane Database of Systematic Reviews. 2026;(9). doi:10.1002/14651858.CD014610.pub2. PMID: 42713852.